NMRA
Neumora Therapeutics Inc. · NASDAQ
- Market cap
- $69.3M
Neumora Therapeutics Inc. (NMRA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for NMRA, including 3 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published Nov 16, 2026.
Financial highlights
Full financials- Net income, TTM
- -$212.75M
- Cash
- $116.83M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks31+100%
2026-05-242026-11-15
Mix1490d
- SEC Filings6(43%)
- Insider6(43%)
- Earnings1(7%)
- 13D/G1(7%)
Activity · 52 weeks6426 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.SCHEDULE 13G/A - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 10-Q filed by Neumora Therapeutics Inc.10-Q - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateIND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study WATERTOWN, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a bus
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- INSIDEROfficer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Berns Paul L4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Duncan Jason4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Milligan Michael Lee4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Pinto Joshua4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- INSIDEROfficer Aurora Daljit Singh exercised 243,753 shares at a strike of $0.72 and sold $431,674 worth of shares (277,773 units at $1.55), decreasing direct ownership by 41% to 48,750 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 10-Q filed by Neumora Therapeutics Inc.10-Q - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateFavorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second half of 2026, respectively Joshua Pinto, Ph.D., appointed chief executive officer and member of the Board of Directors Paul L. Berns appointed Executive Chair, continuing to serve as a key strategic leader to advance Company growth $116.8 million in cash and cash equivalents expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Neumora
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disease. Neumora conducted a repeat 13-week toxicology study in rats following results from a prior study in which unexpected in-life adverse findings were observed in 5 of 142 animals. The Company opened a
- ANALYSTH.C. Wainwright reiterated coverage on Neumora Therapeutics with a new price targetH.C. Wainwright reiterated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $7.00 from $18.00 previously
- ANALYSTNeedham reiterated coverage on Neumora Therapeutics with a new price targetNeedham reiterated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $5.00 from $8.00 previously
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateNavacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027 WATERTOWN, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced
NMRA FAQ
9 questionsWhat is the latest news on NMRA?
In the last 30 days Quantisnow tracked 5 wire items for NMRA: 3 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published on November 16, 2026.Is NMRA profitable?
No. Neumora Therapeutics Inc. reported a net loss of $212.75M for the twelve months ended Jun 30, 2026.How much cash and debt does NMRA have?
Neumora Therapeutics Inc. reported $116.83M in cash and cash equivalents and $112.91M of debt on its most recent balance sheet in SEC filings.Where does NMRA stock trade?
Neumora Therapeutics Inc. (NMRA) is listed on NASDAQ.What sector and industry is NMRA in?
Neumora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Neumora Therapeutics Inc. go public?
Neumora Therapeutics Inc. (NMRA) completed its IPO in 2023.What are analysts saying about NMRA?
Across the last 8 analyst actions on Neumora Therapeutics Inc., there were 3 upgrades and 2 downgrades. The most recent action was from H.C. Wainwright: Buy with a $7.00 price target on 2026-06-16.What companies are similar to NMRA?
Notable peers in the same industry include MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), BIIB (Biogen Inc.), RVMD (Revolution Medicines Inc.), AMGN (Amgen Inc.). Compare NMRA side-by-side with any of them on Quantisnow.How can I track NMRA on Quantisnow?
Quantisnow aggregates Neumora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NMRA to receive live email and push alerts on every new disclosure.